A Study of LY4060874 in Healthy Participants
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
121actual
Sites
2
Countries
Singapore, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-02 | actual | When the study began enrolling |
| Primary completion | 2026-02-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-20 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: LY4060874
- Drug: LY4060874
- Drug: Placebo
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
measured Baseline up to 22 Weeks
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed